



## Description générale

Imatinib is a BCR-ABL tyrosine kinase inhibitor used in treatment protocols for various leukaemias and solid tumours.

INN	Imatinib
Codes ATC	L01EA01
Type de médicament	Chemical agent
Historique des statuts LME	Ajouté pour la première fois en 2015 (TRS 994) pour <b>Chronic myeloid leukaemia, not elsewhere classified</b> Ajouté en 2015 (TRS 994) pour <b>Gastrointestinal stromal tumour of unspecified gastrointestinal sites</b> Ajouté en 2021 (TRS 1035) pour <b>B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1</b>
Wikipédia	<a href="#">Imatinib</a> 
DrugBank	<a href="#">Imatinib</a> 

## Recommandations

### Section Targeted therapies

Oral > Solid: 100 mg; 400 mg

#### Indications

Chronic myeloid leukaemia, not elsewhere classified

Gastrointestinal stromal tumour of unspecified gastrointestinal sites

B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1

